

## Special Issue

# Therapeutic Drug Monitoring in Intensive Care

### Message from the Guest Editors

Antimicrobial dosing in critically ill patients remains a challenging problem. Evidence has shown that for many of the drugs used, the pharmacokinetic variability is huge and may lead to critical under/inadequate dosing in a large number of patients. Although our understanding of the problem has advanced significantly, a host of questions remain, and therapeutic drug monitoring (TDM) is often cited as one of the potential solutions for this problem. In this Special Issue, we wish to focus on different aspects of model-informed precision dosing and TDM in the ICU, including practical issues, technical considerations, performance, application in clinical practice, dosing tools, and other aspects. For this, we will consider different types of manuscripts, as long as they are focused on the topic of this issue. We look forward to your contribution.

### Guest Editors

Prof. Dr. Jan De Waele

Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium

Prof. Dr. Birgit C. P. Koch

Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

### Deadline for manuscript submissions

closed (15 November 2023)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/138001](https://mdpi.com/si/138001)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)